Evidence map›Paper›PMID 26681495›Full record

ArticleBiological psychiatry2016

Genetic Markers of Human Evolution Are Enriched in Schizophrenia.

Saurabh Srinivasan, Francesco Bettella, Morten Mattingsdal, Yunpeng Wang, Aree Witoelar, Andrew J Schork, Wesley K Thompson, Verena Zuber, Schizophrenia Working Group of the Psychiatric Genomics Consortium, The International Headache Genetics Consortium, Bendik S Winsvold and 8 more

Open access · greenAbstract read
In one paragraph

Article in Biological psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 134 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Saurabh SrinivasanNORMENT, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Francesco BettellaNORMENT, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Morten MattingsdalNORMENT, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Yunpeng WangNORMENT, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Multimodal Imaging Laboratory, University of California, San Diego, La Jolla, California.
Aree WitoelarNORMENT, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Andrew J SchorkMultimodal Imaging Laboratory, University of California, San Diego, La Jolla, California; Cognitive Sciences Graduate Program, University of California, San Diego, La Jolla, California; Center for Human Development, University of California, San Diego, La Jolla, California.
Wesley K ThompsonDepartment of Psychiatry, University of California, San Diego, La Jolla, California.
Verena ZuberNORMENT, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Centre for Molecular Medicine Norway, Nordic European Molecular Biology Laboratory Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway.
Schizophrenia Working Group of the Psychiatric Genomics Consortium, The International Headache Genetics Consortium
Bendik S WinsvoldKG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Neurology and Communication and Research Unit at the Division of Neuroscience, Oslo University Hospital, Ullevål, Oslo, Norway.
John-Anker ZwartKG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Neurology and Communication and Research Unit at the Division of Neuroscience, Oslo University Hospital, Ullevål, Oslo, Norway.
David A CollierEli Lilly and Company, Windlesham, Surrey, United Kingdom.
Rahul S DesikanMultimodal Imaging Laboratory, University of California, San Diego, La Jolla, California; Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Ingrid MelleNORMENT, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Thomas WergeInstitute of Biological Psychiatry, Mental Health Center St. Hans, Mental Health Services Copenhagen, Roskilde; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen; The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Capital Region of Denmark, Denmark.
Anders M DaleMultimodal Imaging Laboratory, University of California, San Diego, La Jolla, California; Department of Psychiatry, University of California, San Diego, La Jolla, California; Department of Neuroscience, University of California, San Diego, La Jolla, California; Eli Lilly and Company, Windlesham, Surrey, United Kingdom.
Srdjan DjurovicNORMENT, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Ole A AndreassenNORMENT, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Department of Psychiatry, University of California, San Diego, La Jolla, California. Electronic address: o.a.andreassen@medisin.uio.no.
Oslo University Hospital · NOUniversity of California San Diego · USEli Lilly (United Kingdom) · GBUniversity of California, San Francisco · USUniversity of Copenhagen · DK

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
Alzheimer's Disease Genetics ConsortiumU01AG032984 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2024
$60.4M
CHARGE Consortium: Omics Discovery for CVD and Aging PhenotypesR01HL105756 · NHLBI · UNIVERSITY OF WASHINGTON · PI Bruce M Psaty, NICHOLAS L SMITH · 2011 to 2026
$9.5M
Collaborative GWAS of Dementia, AD and related MRI and Cognitive EndophenotypesR01AG033193 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SESHADRI, SUDHA · 2009 to 2016
$4.4M
5/7 Psychiatric Genomics Consortium: Finding actionable variationU01MH109514 · NIMH · CARDIFF UNIVERSITY · PI O'DONOVAN, MICHAEL · 2016 to 2020
$2.9M
Polygenicity, Pleiotrophy and Power: Novel Statistical Methods for Gene DiscoveryR01GM104400 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI THOMPSON, WESLEY KURT · 2014 to 2017
$1.6M
PATIENT ORIENTED RESEARCH IN BARRETT'S ESOPHAGUSK24DK002800 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI CHAK, AMITABH · 2001 to 2010
$1.6M
NHLBI NIH HHS R01 HL105756NIA NIH HHS R01 AG033193NIA NIH HHS U01 AG016976NIA NIH HHS U01 AG032984NIA NIH HHS U24 AG021886NIDDK NIH HHS K24 DK002800NIGMS NIH HHS R01 GM104400NIMH NIH HHS U01 MH109514Wellcome Trust
6 · The paper itself

Abstract

backgroundWhy schizophrenia has accompanied humans throughout our history despite its negative effect on fitness remains an evolutionary enigma. It is proposed that schizophrenia is a by-product of the complex evolution of the human brain and a compromise for humans' language, creative thinking, and cognitive abilities.

methodsWe analyzed recent large genome-wide association studies of schizophrenia and a range of other human phenotypes (anthropometric measures, cardiovascular disease risk factors, immune-mediated diseases) using a statistical framework that draws on polygenic architecture and ancillary information on genetic variants. We used information from the evolutionary proxy measure called the Neanderthal selective sweep (NSS) score.

resultsGene loci associated with schizophrenia are significantly (p = 7.30 × 10(-9)) more prevalent in genomic regions that are likely to have undergone recent positive selection in humans (i.e., with a low NSS score). Variants in brain-related genes with a low NSS score confer significantly higher susceptibility than variants in other brain-related genes. The enrichment is strongest for schizophrenia, but we cannot rule out enrichment for other phenotypes. The false discovery rate conditional on the evolutionary proxy points to 27 candidate schizophrenia susceptibility loci, 12 of which are associated with schizophrenia and other psychiatric disorders or linked to brain development.

conclusionsOur results suggest that there is a polygenic overlap between schizophrenia and NSS score, a marker of human evolution, which is in line with the hypothesis that the persistence of schizophrenia is related to the evolutionary process of becoming human.

Indexed as

Biological EvolutionBrainGenetic MarkersGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMultifactorial InheritancePolymorphism, Single NucleotideSchizophreniaGenetic MarkersEvolutionGWASHumanNeanderthalPolygenicSchizophrenia

Identifiers

PMID26681495
PMCPMC5397584
OpenAlexW2176749178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.